



Drug Candidates for the Treatment of Multiple Myeloma

Guest Editor:

Dr. Akinobu Ota

Department of Biochemistry,
Aichi Medical University School of
Medicine, Building No 2, 1-1
Yazakokarimata, Nagakute, Aichi
480-1195, Japan

Deadline for manuscript
submissions:

closed (15 July 2023)

Message from the Guest Editor

Dear Colleagues,

Multiple myeloma (MM) is an incurable B cell malignancy caused by the abnormal expansion of bone marrow-derived plasma cells, and gives rise to clinical symptoms including bone pain, anemia, hypercalcemia and patients becoming immunocompromised.

The treatment of patients with MM has much improved during the recent two decades, in which immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), monoclonal antibodies against immune cell surface markers play an important role as novel agents to treat MM.

Meanwhile, researchers have characterized that MM cells possess a number of common genomic alterations including somatic mutations, chromosomal amplification/deletion, some of which could represent druggable molecular target and certain drug sensitivity to current therapeutics.

The journal *Pharmaceuticals* invites both reviews and original articles scoping on the challenges and opportunities specific to MM. Topics include novel drug candidates, such as molecular-targeted drugs, immunomodulatory drugs, proteasome inhibitors, chimeric antigen receptor T cells, and immune check point inhibitors.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com